Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C49H62N10O16S3 |
Molecular Weight | 1143.269 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](NC(=O)[C@H](CC1=CC=C(OS(O)(=O)=O)C=C1)NC(=O)[C@@H](N)CC(O)=O)C(=O)NCC(=O)N[C@@H](CC2=CNC3=C2C=CC=C3)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC4=CC=CC=C4)C(N)=O
InChI
InChIKey=IZTQOLKUZKXIRV-YRVFCXMDSA-N
InChI=1S/C49H62N10O16S3/c1-76-18-16-34(55-47(69)37(58-44(66)32(50)23-41(61)62)21-28-12-14-30(15-13-28)75-78(72,73)74)45(67)53-26-40(60)54-38(22-29-25-52-33-11-7-6-10-31(29)33)48(70)56-35(17-19-77-2)46(68)59-39(24-42(63)64)49(71)57-36(43(51)65)20-27-8-4-3-5-9-27/h3-15,25,32,34-39,52H,16-24,26,50H2,1-2H3,(H2,51,65)(H,53,67)(H,54,60)(H,55,69)(H,56,70)(H,57,71)(H,58,66)(H,59,68)(H,61,62)(H,63,64)(H,72,73,74)/t32-,34-,35-,36-,37-,38-,39-/m0/s1
Sincalide is a synthetically-prepared C-terminal octapeptide of naturally occurring hormone cholecystokinin. Sincalide causes gallbladder contraction and stimulates secretion of pancreatic enzymes, and this property of the drug is used in diagnostic purposes. It is discussed that the drug acts by binding and stimulating the CCK-A receptor which is expressed in the target tissues. FDA approved sincalide under the name KINEVAC.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1901 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159891 |
1.4 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | KINEVAC Approved UseKinevac (Sincalide for Injection) may be used: (1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. Launch Date1976 |
|||
Diagnostic | KINEVAC Approved UseKinevac (Sincalide for Injection) may be used: (1) to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. Launch Date1976 |
Sample Use Guides
For prompt contraction of the gallbladder, a dose of 0.02 mcg sincalide per kg (1.4 mcg/70 kg) is injected intravenously over a 30- to 60-second interval. For the test of pancreatic function, the patient receives a dose of 0.25 units secretin per kg by intravenous infusion over a 60-minute period. Thirty minutes after the initiation of the secretin infusion, a separate IV infusion of sincalide at a total dose of 0.02 mcg per kg is administered over a 30-minute interval. To accelerate the transit time of a barium meal through the small bowel, the drug should be given at a dose of 0.04 mcg sincalide per kg (2.8 mcg/70 kg) injected intravenously over a 30- to 60- second interval.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11159891
Muscle cells of gallbladders were exposed to sincalide (10(-7)-10(-13) M) for 30 sec to induce cells contraction.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175798
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
||
|
NDF-RT |
N0000007750
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
||
|
NDF-RT |
N0000007750
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
||
|
WHO-ATC |
V04CC03
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
||
|
NDF-RT |
N0000007750
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
||
|
WHO-VATC |
QV04CC03
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000083517
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
Sincalide
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
3617
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
M03GIQ7Z6P
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
SUB10531MIG
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
D012844
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
DTXSID7048617
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
25126-32-3
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
M03GIQ7Z6P
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
4627
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
9800
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
m9951
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
C47719
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
9833444
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
DB09142
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
246-639-0
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
SINCALIDE
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL1121
Created by
admin on Fri Dec 15 15:47:40 GMT 2023 , Edited by admin on Fri Dec 15 15:47:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY